<?xml version="1.0" encoding="UTF-8"?>
<p>Approximately 17 million patients have access to antiretroviral therapy capable of controlling viremia and reducing mortality [
 <xref rid="B61-molecules-25-00942" ref-type="bibr">61</xref>]. However, long-term treatment with antiretroviral agents can lead to drug resistance due to rapid mutations in the viral genome resulting in RT mutations and HIV chemotherapy failure [
 <xref rid="B62-molecules-25-00942" ref-type="bibr">62</xref>]. These concerns have attracted a particular focus on research into new antiretroviral drugs that address the limitations of currently available agents for the treatment of HIV infection [
 <xref rid="B46-molecules-25-00942" ref-type="bibr">46</xref>,
 <xref rid="B59-molecules-25-00942" ref-type="bibr">59</xref>].
</p>
